Literature DB >> 31187896

Tissue Engineering of the Microvasculature.

Joe Tien1,2.   

Abstract

The ability to generate new microvessels in desired numbers and at desired locations has been a long-sought goal in vascular medicine, engineering, and biology. Historically, the need to revascularize ischemic tissues nonsurgically (so-called therapeutic vascularization) served as the main driving force for the development of new methods of vascular growth. More recently, vascularization of engineered tissues and the generation of vascularized microphysiological systems have provided additional targets for these methods, and have required adaptation of therapeutic vascularization to biomaterial scaffolds and to microscale devices. Three complementary strategies have been investigated to engineer microvasculature: angiogenesis (the sprouting of existing vessels), vasculogenesis (the coalescence of adult or progenitor cells into vessels), and microfluidics (the vascularization of scaffolds that possess the open geometry of microvascular networks). Over the past several decades, vascularization techniques have grown tremendously in sophistication, from the crude implantation of arteries into myocardial tunnels by Vineberg in the 1940s, to the current use of micropatterning techniques to control the exact shape and placement of vessels within a scaffold. This review provides a broad historical view of methods to engineer the microvasculature, and offers a common framework for organizing and analyzing the numerous studies in this area of tissue engineering and regenerative medicine. © 2019 American Physiological Society. Compr Physiol 9:1155-1212, 2019.
Copyright © 2019 American Physiological Society. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31187896      PMCID: PMC7025285          DOI: 10.1002/cphy.c180037

Source DB:  PubMed          Journal:  Compr Physiol        ISSN: 2040-4603            Impact factor:   9.090


  659 in total

1.  3D systems delivering VEGF to promote angiogenesis for tissue engineering.

Authors:  Anne des Rieux; Bernard Ucakar; Billy Paul Kaishusha Mupendwa; Didier Colau; Olivier Feron; Peter Carmeliet; Véronique Préat
Journal:  J Control Release       Date:  2010-12-03       Impact factor: 9.776

2.  An arteriovenous loop in a protected space generates a permanent, highly vascular, tissue-engineered construct.

Authors:  Zerina Lokmic; Filip Stillaert; Wayne A Morrison; Erik W Thompson; Geraldine M Mitchell
Journal:  FASEB J       Date:  2006-12-16       Impact factor: 5.191

3.  Prox1 function is required for the development of the murine lymphatic system.

Authors:  J T Wigle; G Oliver
Journal:  Cell       Date:  1999-09-17       Impact factor: 41.582

4.  Thoracic Surgery Directors Association Award. Angiogenesis in transmyocardial revascularization: comparison of laser versus mechanical punctures.

Authors:  V F Chu; A Giaid; J Q Kuang; A N McGinn; C M Li; M P Pelletier; R C Chiu
Journal:  Ann Thorac Surg       Date:  1999-08       Impact factor: 4.330

5.  Coadministration of basic fibroblast growth factor and sucrose octasulfate (sucralfate) facilitates the rat dorsal flap survival and viability.

Authors:  M A Rashid; S Akita; M S Razzaque; H Yoshimoto; H Ishihara; T Fujii; K Tanaka; T Taguchi
Journal:  Plast Reconstr Surg       Date:  1999-03       Impact factor: 4.730

6.  Hyperbaric oxygen induces basic fibroblast growth factor and hepatocyte growth factor expression, and enhances blood perfusion and muscle regeneration in mouse ischemic hind limbs.

Authors:  Tetsuichi Asano; Eiji Kaneko; Shohei Shinozaki; Yutaka Imai; Masaharu Shibayama; Tsuyoshi Chiba; Masumi Ai; Akio Kawakami; Hiroshi Asaoka; Toru Nakayama; Yoshihiro Mano; Kentaro Shimokado
Journal:  Circ J       Date:  2007-03       Impact factor: 2.993

7.  Basic fibroblast growth factor enhances myocardial collateral flow in a canine model.

Authors:  E F Unger; S Banai; M Shou; D F Lazarous; M T Jaklitsch; M Scheinowitz; R Correa; C Klingbeil; S E Epstein
Journal:  Am J Physiol       Date:  1994-04

8.  Bioartificial matrices for therapeutic vascularization.

Authors:  Edward A Phelps; Natalia Landázuri; Peter M Thulé; W Robert Taylor; Andrés J García
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-31       Impact factor: 11.205

9.  Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels.

Authors:  Petra Korpisalo; Henna Karvinen; Tuomas T Rissanen; Johanna Kilpijoki; Varpu Marjomäki; Peter Baluk; Donald M McDonald; Yihai Cao; Ulf Eriksson; Kari Alitalo; Seppo Ylä-Herttuala
Journal:  Circ Res       Date:  2008-10-02       Impact factor: 17.367

10.  Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1alpha variant for local induction of angiogenesis.

Authors:  Diana Trentin; Heike Hall; Sandra Wechsler; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

View more
  5 in total

Review 1.  Oral mucosa equivalents, prevascularization approaches, and potential applications.

Authors:  Daniela S Masson-Meyers; Luiz E Bertassoni; Lobat Tayebi
Journal:  Connect Tissue Res       Date:  2022-02-08       Impact factor: 3.342

Review 2.  Microfluidic Biomaterials.

Authors:  Joe Tien; Yoseph W Dance
Journal:  Adv Healthc Mater       Date:  2020-09-06       Impact factor: 9.933

Review 3.  Vascularization strategies in tissue engineering approaches for soft tissue repair.

Authors:  Daniela Santos Masson-Meyers; Lobat Tayebi
Journal:  J Tissue Eng Regen Med       Date:  2021-05-31       Impact factor: 4.323

Review 4.  Microvascular Tissue Engineering-A Review.

Authors:  Jernej Vajda; Marko Milojević; Uroš Maver; Boštjan Vihar
Journal:  Biomedicines       Date:  2021-05-21

Review 5.  Vascularized Microfluidics and Their Untapped Potential for Discovery in Diseases of the Microvasculature.

Authors:  David R Myers; Wilbur A Lam
Journal:  Annu Rev Biomed Eng       Date:  2021-04-16       Impact factor: 9.590

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.